institutionsInstitution
Karolinska University Hospital
Sweden's leading cancer hospital, linked to the Karolinska Institutet and Nobel Assembly, with strong registry-based research.
Comprehensive Cancer Centre; national quality registries enabling real-world evidence; Skandion proton clinic (Uppsala) collaboration.
Location
Stockholm, SE
Type
university · Karolinska Institutet
Website
Newsweek 2026 oncology rank
#39
OnCo score
#36 · 53 points (21 Newsweek + 0 NCI + 32 from 16 linked objects) · ranking
- Registry research
- Haematology
Hans-Gustaf Ljunggren
Professor of Infectious Medicine, Karolinska Institutet; Center for Infectious Medicine
NK cell biologyMissing-self recognitionCell therapy
Hans-Gustaf Ljunggren proposed the missing-self hypothesis of NK cell recognition.
Jonas Bergh
Professor of Oncology, Karolinska Institutet; Senior Physician, Karolinska University Hospital
Breast cancerAdjuvant therapyDose-dense chemotherapy
Jonas Bergh is a breast oncologist and long-standing leader of Swedish and European breast cancer trials.
Per Hall
Professor of Radiation Epidemiology, Karolinska Institutet
Breast cancer epidemiologyRisk-based screeningMammographic density
Per Hall is the epidemiologist behind KARMA and the risk-based breast screening programme.
Rolf Kiessling
Professor of Experimental Oncology, Karolinska Institutet
Tumour immunologyNatural killer cellsCancer vaccines
Rolf Kiessling is the immunologist who first described natural killer cells.
institutions
7HUS Comprehensive Cancer Center, Helsinki University HospitalNordic Lymphoma GroupOrganisation of European Cancer InstitutesOslo University Hospital – The Norwegian Radium HospitalSahlgrenska University Hospital / Sahlgrenska Center for Cancer ResearchSkåne University Hospital / Lund University Cancer CentreUppsala University Hospital / Uppsala University
terms
1trials
1ideas
6A lifelong late-effects registry linked to every treatment for adult survivorsGet biomarker-directed aspirin after colorectal surgery into labels and guidelinesLink bariatric and GLP-1 registries to cancer registries in every country that has bothRandomise inside the cancer registry: registry-based trials for everyday questionsRegistry-based randomised MCED trial: a million people, no study visitsRegistry-based randomised trials for oncology comparative effectiveness